Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for investment professionals · Wednesday, January 16, 2019 · 473,789,302 Articles · 3+ Million Readers

M&A Activities in the Pharma Contract Manufacturing Industry, Focus on 2015-2017

/EIN News/ -- Dublin, Jan. 11, 2019 (GLOBE NEWSWIRE) -- The "PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" report has been added to ResearchAndMarkets.com's offering.

"PharmSource - M&A in the Contract Manufacturing Industry: Implications and Outlook - 2018 Edition" analyzes merger and acquisition (M&A) activity in the pharmaceutical contract manufacturing industry during the period 2015-2017. The services considered in this report are contract manufacturing of active pharmaceutical ingredients (APIs) and finished dose products, associated analytical services, and packaging. Contract research providers were excluded.

Mergers and Acquisitions of companies and facilities have been a high profile feature of the pharmaceutical CMO industry in current times. Acquisition deals consistently receive high profile coverage in industry news media, with questions surrounding valuations, strategic intent and which companies are potentially next targets continuously debated in the industry.

There were 130 acquisitions of service providers during the three-year period from 2015-2017. The majority of acquisitions targeted contract manufacturing organizations (CMOs) that focused on APIs-small molecule, dose, and analytical services. Nearly 70% of acquirers of services companies were strategic acquirers, that is, they were operating companies rather than investment firms. A few services companies changed hands as a consequence of the purchase of their parent company, while several CMOs were acquired by bio/pharma companies seeking to secure product supply.

More than half of acquirers were public companies, although 36% of company acquisitions were by PE firms or by CMOs owned by PE firms, with a high level of influence on the industry. Companies with complex technologies, including biologics manufacturing, are likely to be sought-after targets, as well as CMOs with specialized capabilities. However, in the coming years, M&A activity will be hindered by higher interest rates, uncertain trade and investment policies, high valuation expectations, and sizeable debt loads carried by some of the most active acquirers.

Scope

  • Helps bio/pharmaceutical manufacturing, development, and supply chain executives understand the implications of M&A activity on their supply base and sourcing options.
  • Helps executives at CMOs and associated contract services companies and investors to recognize the significance of M&A activities for the competitive dynamics of the industry and how company strategies must change to address the altering market.
  • To gain insights that might enable predictions of the nature and implications of M&A activity in the next three to five years.

Reasons to Buy

  • CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
  • Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
  • Private equity and Stock analysts: target identification and analysis, portfolio company performance benchmarking.

Key Topics Covered:

1. Executive Summary

2 Objectives and Methodology

3 Overview of M&A Activity 2015-2017
Target Characteristics
Acquirer Characteristics

4 Segment Close-Ups of M&A Activity, 2015-2017
Dose Manufacturing
API - Biologic
API - Small Molecule
Analytical Services
Formulation and Clinical Supplies Manufacturing
Packaging

5 Valuations

6 Facility Acquisitions

7 What It Means

8 The Outlook for M&A in the Manufacturing Services Industry

9 Notes on Methodology

10 Appendix
Service Acquisitions 2015-2017
Bibliography
Primary Research - Key Opinion Leaders Cited in this Report

Companies Mentioned

  • 3SBio
  • ABC Laboratories
  • Absorption Systems
  • Abzena
  • Acacia Lifesciences
  • Accucaps
  • Accuratus Lab Services
  • Advanced BioScience Laboratories
  • Advantar Laboratories
  • Aeras
  • Agere Pharmaceuticals
  • AGIC Capital
  • Ajinomoto
  • Akorn

For more information about this report visit https://www.researchandmarkets.com/research/rh66kf/manda_activities?w=12

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    
                    

22157.jpg

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release